Real Questions and latest syllabus of 156-730 exam

From killexams.com, all of us give valid or even more today Checkpoint 156-730 Practice Questions that are accessible for download within just one click on. We tend not to recommend wasting your own time on totally free stuff. Just indication-up for the little payment plus obtain your Check Point Accredited Sandblast Administrator Test Prep download account ready within a short while. Study our 156-730 Practice Questions and complete your exam.

Exam Code: 156-730 Practice exam 2022 by Killexams.com team
Check Point Accredited Sandblast Administrator
Checkpoint Administrator approach
Killexams : Checkpoint Administrator approach - BingNews https://killexams.com/pass4sure/exam-detail/156-730 Search results Killexams : Checkpoint Administrator approach - BingNews https://killexams.com/pass4sure/exam-detail/156-730 https://killexams.com/exam_list/Checkpoint Killexams : Hakimo AI to Help Reduce Unauthorized Access at Punta Gorda TSA Checkpoint

Hakimo has announced that Punta Gorda Airport (PGD) has deployed the company’s solution to enhance security and support Transportation Security Administration (TSA) compliance efforts.

PGD turned to Hakimo to help monitor for and reduce incidents of unauthorized access by people and vehicles (piggybacking and tailgating) at the airport. U.S. airports are required to implement access control measures to prevent unauthorized access as part of their airport security program which is approved and checked by the TSA. The Hakimo software helps address these requirements by applying artificial intelligence to the airport’s existing access control and video surveillance systems.

“You can have countless policies and procedures in place, but you don’t really know what’s happening unless you have a guard at every access point,” said Raymond Laroche, Director of Operations and Maintenance, PGD. “The Hakimo AI software is that guard.”

“It has been a privilege to work with the stellar security team at PGD to implement Hakimo’s  advanced AI technology,” said Samuel Joseph, Co-Founder and CEO, Hakimo. “PGD is already known in the aviation industry for their forward-thinking approach to security, and this further  supports their vision.”

Hakimo artificial intelligence algorithms make it possible to automatically analyze video corresponding to every badge swipe and detect piggybacking or tailgating if and when it occurs by looking at the number of unique individuals or vehicles going through the opening. The artificial intelligence software can then provide the security team with a real-time alert when it detects piggybacking or tailgating. This provides organizations with a scalable way to accurately determine piggybacking or tailgating. For compliance and forensic purposes, they also have a way to easily share video clips with external authorities.

The Hakimo software also helps change behavior in support of security programs. It can automatically send an email to a badge holder when there’s a tailgating violation, or the security team can speak with them directly to let them know about the issue. This results in real behavior change in badge holders, as seen in practice at PGD. 

Finally, with actionable insights from the Hakimo artificial intelligence solution, security teams can guide security system maintenance and help inform security programs and planning. This includes uncovering potential insider threats, changing employee behavior, and identifying faulty hardware.

Read more at Hakimo

Mon, 08 Aug 2022 03:41:00 -0500 en-US text/html https://www.hstoday.us/industry/industry-news/hakimo-ai-to-help-reduce-unauthorized-access-at-punta-gorda-tsa-checkpoint/
Killexams : Checkpoint Capital Names Jack Stimac as President and Head of Financial Strategies

AUSTIN, Texas--(BUSINESS WIRE)--Aug 8, 2022--

Checkpoint Capital, LLC, a FinTech capital markets specialist firm supporting depository institutions, has named John C. “Jack” Stimac, Jr. as President and Head of Financial Strategies, effective immediately.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220805005499/en/

Jack Stimac, President and Head of Financial Strategies, Checkpoint Capital, LLC (Photo: Business Wire)

Working alongside Checkpoint Capital Founder and Chairman Jon Virostek and CEO Billy Weber, Jack will focus on the expansion and implementation of the firm’s premier fixed income price transparency model at community banks across the U.S.

He joins the firm with an extensive background in financial services of nearly 20 years. Most recently he was at Baird, serving as Director, Fixed Income Capital Markets, in Memphis, TN, and prior to that, at Wells Fargo Securities as Director, Fixed Income Market & Portfolio Strategy. His responsibilities have included advising depository institutions on product selection, curve positioning, and cash flow management to best meet their obligations and maximize income. In previous roles, Jack reviewed portfolios for swap ideas that helped customers enhance performance or Strengthen the overall liquidity profile of their bond portfolios and recommended and executed over $10 billion in ALM asset repositioning transfers to Strengthen capital treatment.

“Jack is a talented and highly skilled executive with a deep understanding of fixed-income market dynamics,” said Jon Virostek. “His proven expertise in financial strategies, combined with our technology platform and suite of services, will enable us to pursue new relationships in community banking while continuing to provide the outstanding service our valued clients have come to expect from us.”

Checkpoint Capital’s products and services enable community banks affordable access to the types of fixed income investment opportunities utilized by many of the world’s largest financial institutions.

“We have embarked on a strategy to empower community banks with fixed income price transparency and are gratified by the increasing acceptance and adoption of our insights, processes, and tools,” said Billy Weber, CEO, Checkpoint Capital, LLC. “This a significant and complementary hire for Checkpoint and its client base, adding to our existing deep bench of talent, which includes regulatory, investment banking, capital markets, and trading expertise. With Jack joining as head of financial strategies, we are well situated to further expand our capabilities in the community banking industry.”

Checkpoint Capital’s transparency model is resonating with the depository industry. The firm has continued to capture market share, with its quarterly growth rates as high as 500% since inception in late 2018. Community banks working with Checkpoint benefit from transparent transaction costs for their fixed income portfolios, cutting-edge trading platforms, Asset Liability Management (ALM), and portfolio analytics, which have been the primary performance drivers for the firm.

“I think our fixed income price transparency model is already changing the way community banks buy bonds,” said Jack Stimac, President, Checkpoint Capital. “By helping financial institutions Strengthen returns with better execution in their bond portfolios, we are delivering a legitimate, quantifiable value-add to our customers.”

Jack graduated from the University of Richmond with a Bachelor of Science in Business Administration, with concentrations in Finance and Economics. He is a Chartered Financial Analyst (CFA), is a member of the CFA Institute and CFA Memphis, and holds FINRA Licenses Series 7, 63, 86 and 87.

About Checkpoint Capital, LLC

Checkpoint Capital, LLC offers community banks affordable access to the latest financial technology and analytical tools in order to better understand their unique fixed-income investment needs and gain greater price transparency in the bond market. Its resources level the playing field with large institutions and empower community banks to lower costs, increase efficiencies and better manage risk.

Checkpoint maintains a number of strategic alliances to bring a full suite of solutions in support of community banks and credit unions. Its offerings include Asset Liability Management (ALM), Bond Portfolio Accounting, Strategic Planning, Liquidity Stress Testing, Deposit Analytics and Credit Stress Testing to institutions of all sizes on an on-premise, cloud or outsource service basis.

Disclosures

Expressions of opinion specifically contained in this press release are as of this date and are subject to change without notice. Registered Representatives in this office are registered with and securities offered through Cantella & Co., Inc. MemberFINRA|SIPC. 389 Main Street Malden, MA 02109 (800) 333-3502. Checkpoint Capital, LLC is not affiliated with Cantella & Co., Inc. This information is not intended as a solicitation of an offer to buy or sell, and security referred herein. Past performance may not be indicative of future results.

View source version on businesswire.com:https://www.businesswire.com/news/home/20220805005499/en/

CONTACT: Laura Hynes-Keller

LHK Communications, LLC

+1-212-758-8602 |laura@lhkcommunications.com

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: PROFESSIONAL SERVICES DATA ANALYTICS FINANCE FINTECH ASSET MANAGEMENT BANKING

SOURCE: Checkpoint Capital, LLC

Copyright Business Wire 2022.

PUB: 08/08/2022 10:00 AM/DISC: 08/08/2022 10:02 AM

http://www.businesswire.com/news/home/20220805005499/en

Mon, 08 Aug 2022 02:02:00 -0500 en text/html https://www.joplinglobe.com/region/national_business/checkpoint-capital-names-jack-stimac-as-president-and-head-of-financial-strategies/article_468736ae-02da-5280-8f4f-2067a6496702.html
Killexams : Security Startups Focus on 3 Key Areas

The RSA Conference is the industry’s biggest cybersecurity show, and it hosts the premier startup competition, Innovation Sandbox. In the competition, 10 entrepreneurs pitch their startups to a panel of investors and industry luminaries. Forecasters and early adopters take note: For over a decade, this competition has produced major brands like Cylance, SentinelOne, Cybereason, and many others.

This year Talon Security won by making a bold but convincing case that it might be the corporate web browser of the future. Judge and VP for products at Check Point Technologies, Dorit Dor, called Talon a “legit alternative” to existing players.

Talon Security pointed out how difficult it is to deploy security controls and software across heterogeneous devices accessing an organization’s clouds. Many of these are third-party devices, but they all have users who can install a web browser. That’s something that doesn’t even require admin privileges. Since Talon has joined Microsoft on Google’s Chromium code base, Talon’s browser will have near-universal device and web compatibility.

Talon customers would require this browser to use their cloud, so they can manage privileges centrally. This hardened browser can keep privileged data contained within it, blocking cut and paste, screen capping, and saving.

These 10 finalists, the business problems they solve, and their visions for the future are quite different from past industry thinking. Three distinct trends emerged:

Also see: The Successful CISO: How to Build Stakeholder Trust

1) Post-Cloud IT Infrastructure and its Security is Still Under Construction

BastionZero

Fans of blockchain have long awaited its impact on the cybersecurity industry. BastionZero’s founders are both academic crypto researchers, who created a blockchain security startup before deciding to decentralize zero trust.

Founder Sharon Goldberg speaks passionately as to how zero-trust thinking is fundamentally flawed due to centralization. Inspired by the crypto ethos, BastionZero brings a decentralized solution based on multiple roots of trust. If one root is compromised, organizations will still maintain control. It allows engineers and build processes secure access to their clouds, with recorded sessions that can be replayed during audits.

SevCo

Carbon Black founder, JJ Guy, and Cylance founder, Greg Fitzgerald, showcased their cloud-native asset intelligence startup, SevCo. Numerous systems claim to provide point-in-time inventories of devices, but they’re never correct. With virtual workers, third-party contractors, and unmanaged devices accessing the cloud, the problem is only getting worse.

SevCo’s real-time streaming platform is powered by a correlation engine. It continuously collects and dedupes device telemetry, even scraping adjacent device information from Address Resolution Protocol (ARP) tables. After generating the most up-to-date inventories, it’ll be curious to see if SevCo can conquer the difficult problem of identifying Internet of Things (IoT) and unmanaged devices.

Also see: Secure Access Service Edge: Big Benefits, Big Challenges

2) Security Doesn’t Revolve Around the CISO

Most of the prior years catered to those hunting threats and reporting to the CISO. This year, startups are rethinking core IT infrastructure security around the cloud transformation.

Talon’s web browser, SevCo’s IT inventory, and BastionZero’s authentication are more likely sold to buyers under the CIO. The next three finalists continue this trend. They manage risk across data, privacy, and DevOps teams while defending the digital transformation.

Dasera

“DataGovOps is going to be the next revolution,” said David McCaw, founder of Dasera.

He built Dasera to free data security that’s siloed within separate DataOps, ITOps, and PrivacyOps teams. Using API integrations, Dasera maps data and context and automates workflows and policy management.

Cycode

In years past, Innovation Sandbox has incubated SecDevOps startups into an already crowded marketplace. Here, judges pointed out this challenge of the tough market. Yet Cycode stood strong, articulating its focus on the full software development lifecycle. Cycode spans from application code to the complexity of open-source libraries. It manages the complex deployment paths that caused the Log4J vulnerability to linger.

Torq

Innovation Sandbox has launched security orchestration startups in the past. In 2022, Torq ushers in the next generation. Torq removes the need for Python coding with a no-code approach, allowing security experts to visually build automation for incident response. Torq is built for users across organizational departments. It allows security workflows that can ask IT for things like account provisioning and asks end users for permission grants.

Also see: Best Website Scanners 

3) APIs and Vulnerabilities Overshadow Malware in Cloud Security

This is the second straight year purpose-built malware detection has been missing from the finals. While surprising to some, the judges have their reasons.

While still widely used against endpoints, placing malware in the cloud, and hoping it falls near privileged data is a low-probability tactic. At this time, cloud security is more about stealing and using credentials. Credentials enable adversaries to log in across the multicloud’s broad identity layer, then access assets with APIs. While the origin point of API attacks could be malware, many believe API attacks often originate from a hacker’s own device, sitting behind an anonymized IP.

The remaining finalists directly secure cloud applications and assets, either from API attacks or by detecting and remediating cloud vulnerabilities and over permissions. While none specifically bring malware detection, several provide more visibility into cloud workloads.

Neosec

Neosec is an application security company defending B2B APIs by leveraging API gateways like Google Apigee. Neosec identifies an organization’s APIs, detects vulnerabilities, and uses behavioral analytics to visualize misuse and abuse. It also includes a managed service to aid customers in handling these new and complex API attacks.

Lightspin

Lightspin makes cloud-native app protection easy with its graph technology. Their visualization is best described as constructed backward from valuable assets. It illustrates the critical path of vulnerable or misconfigured nodes that hackers might work through to reach sensitive data.

Araali Networks

Araali Networks embraces agent deployment frameworks supplied by Kubernetes. They’re creating an agent-based threat management solution to protect private clouds. Araali monitors network traffic, enforces explicit policies, and blocks threatening code.

Cado Security

Cado Security takes a unique forensics and incident response approach to cloud workloads. Instead of playing the difficult agent game, Cado leverages cloud providers to access cloned point-in-time images of workloads. When done near the time of security alerts, this provides valuable offline forensics.

Cloud forensics has big potential. This offline analysis has zero impact on high availability workloads. It allows examining both binary files inside workloads and forensic evidence of running processes. Cado Security doesn’t boast specific malware detection but allows searching for malware indicators.

Also see: Real Time Data Management Trends

Evolving to Keep Up With Digital Transformation

For years hackers breached the perimeter, deployed malware, and worked their way inside on-premises networks towards data. That world is in decline. At Innovation Sandbox, we got to witness a new species of cybersecurity, a species evolving to keep pace with an ever-changing IT infrastructure and the digital transformation.

About the author:

Paul Shomo is a media correspondent and contributor to eWeek. A cybersecurity analyst, he was one of the engineering leaders behind the security forensics brand, EnCase.

Fri, 29 Jul 2022 10:22:00 -0500 en-US text/html https://www.eweek.com/security/security-startups-it-infrastructure/
Killexams : Check Point Software reports significantly accelerated growth for the second quarter

Check Point Software Technologies Ltd. today posted second-quarter revenue and adjusted earnings that reached the high end of its guidance.

Check Point Software is one of the top providers of cybersecurity software for the enterprise. The company sells products that help organizations secure their cloud environments, protect employee  devices and scan network traffic for malicious requests.

Check Point Software’s revenues reached $571 million in the second quarter after growing 9% year-over-year. Compared with the second quarter of fiscal 2021, the company has more than doubled its growth rate. Deferred revenues, a measure of future sales, increased at an even faster rate of 14% to reach $1.66 billion.

Check Point Software pointed to strong demand for its Harmony suite of cybersecurity products as one factor behind its accelerated quarterly growth. 

Companies use Harmony to help employees securely log into work applications. Additionally, the product suite includes tools that block phishing campaigns and protect employee devices from malware. Check Point Software detailed today that the Harmony suite experienced more than 50% growth in the second quarter.

CloudGuard and Quantum, Check Point Software’s two other flagship product suites, both experienced double-digit growth as well during the three months ended June  30. CloudGuard is a suite of tools designed to help companies secure their public cloud environments. Quantum, in turn, is Check Point Software’s lineup of on-premises firewall appliances and related software products.

Harmony, CloudGuard and parts of the Quantum product portfolio together form Check Point Software’s security subscriptions revenue segment. The segment grew 14% year-over-year in the second quarter, to $210 million.

Check Point Software’s product and license revenues segment, which includes offerings such as its Quantum firewalls, experienced 12% growth. It accounted for $133 million of the company’s total revenue during the three months ended June 30.

The $571 million in total revenue that Check Point Software generated puts the company $11 million above the midpoint of its guidance for the second quarter. Furthermore, the company reached the high end of its adjusted earnings forecast. Check Point Software closed the second quarter with adjusted earnings of $1.64 per share, foir cents above the midpoint of its forecast and 2% more than a year ago. 

“Over the past quarter, cyber-attacks have increased by 32 percent while advanced attacks like ransomware have grown by 59 percent, underscoring why cyber-security is so critical to keep our world going,” said Check Point Software founder and Chief Executive Officer Gil Shwed. “Our strategic vision of a consolidated prevention-first security architecture is more relevant than ever to combat today’s cyber challenges.”

For the third quarter, Check Point Software is projecting revenues of $555 million to $585 million. The company expects its adjusted earnings to range between $1.6 and $1.72 per share. 

Image: Check Point Software

Show your support for our mission by joining our Cube Club and Cube Event Community of experts. Join the community that includes Amazon Web Services and Amazon.com CEO Andy Jassy, Dell Technologies founder and CEO Michael Dell, Intel CEO Pat Gelsinger and many more luminaries and experts.

Mon, 01 Aug 2022 12:53:00 -0500 en-US text/html https://siliconangle.com/2022/08/01/check-point-software-reports-significantly-accelerated-growth-second-quarter/
Killexams : A cybersecurity expert explains why it’s time to get serious about Zero Trust No result found, try new keyword!The Biden administration has now even mandated it ... checked your identity when you passed through the initial security checkpoint. Theoretically, once you’re in the concourse, you’d be ... Thu, 30 Jun 2022 02:07:00 -0500 en-us text/html https://www.msn.com/en-us/news/technology/a-cybersecurity-expert-explains-why-it-s-time-to-get-serious-about-zero-trust/ar-AAZ2v86 Killexams : How a small UK biotech ended up in Gilead’s hands

Gilead Sciences will acquire U.K.-based startup MiroBio, which is developing antibody drugs for autoimmune disorders, in a $405 million deal announced Thursday.

MiroBio sprouted from a University of Oxford research laboratory run by professors Simon Davis and Richard Cornall. Its approach focuses on checkpoint receptors, proteins that help to regulate the immune system.

Blocking these proteins has proven effective in treating cancer, unleashing the immune system to attack malignant cells. But companies like MiroBio are exploring how they can be targeted to tamp down damaging immune system overreactions in inflammatory diseases.

Existing autoimmune disease drugs generally reduce the overall amount of inflammation in the body. By comparison, MiroBio aims to use antibodies to selectively stimulate the immune system’s “brakes,” finding the correct checkpoint receptor to block overactive immune cells.

Striking this balance is tricky, but more precise treatments could help people with autoimmune diseases without leaving them vulnerable to infections.

MiroBio’s most advanced experimental antibody, dubbed MB272, targets T, B and dendritic cells to rein in inflammatory immune responses. MB272 entered Phase 1 clinical trials this week as the deal with Gilead was announced.

The company’s other drug, a PD-1 agonist, is in preclinical testing.

Backed by Samsara BioCapital and Oxford Sciences Enterprises, MiroBio was spun out of Oxford in 2019. Cofounder Cornall had previously worked at Stanford University with Samsara’s founder Srini Akkaraju, who connected Cornall with Eliot Charles. An alum of Genentech and Amgen who had recently landed in the U.K., Charles is now chair of MiroBio’s board of directors.

MiroBio raised $33 million in a Series A round in 2019, and added another $97 million in Series B funding in June.

According to Charles, MiroBio did not set out seeking an acquisition. But he said the startup had received “an awful lot of interest” since 2019, and began talking to Gilead more seriously late last year

“Market conditions were bad, but we managed to raise more than $100 million and that’s a testament to the people,” he said.

MiroBio’s preclinical data attracted Gilead, which plans to generate additional drugs targeting immune receptors from MiroBio’s research platform. The acquisition expands Gilead’s presence in anti-inflammatory disease, a corner of their research alongside a longstanding focus on HIV and hepatitis C.

“We perceive [the deal] more as a continuation rather than a shift back to inflammation and consistent with their overall business development strategy to do smaller-sized deals,” said Salim Syed, a biotech analyst at Mizuho Securities.

Gilead has eyed a larger business in anti-inflammatory drugs with its substantial $5 billion investment in Belgian biotech Galapagos. But in 2020, the Food and Drug Administration rejected filgotinib, one of Galapagos’ most important drugs.

Immune diseases have drawn significant investment from other large pharmaceutical companies, such as Eli Lilly and Merck & Co., who are interested in new, more targeted anti-inflammatory approaches. In 2021, Merck acquired Pandion Therapeutics in a $1.9 billion deal. At the time, Pandion had reported positive results from a Phase 1 clinical trial testing a treatment for ulcerative colitis and lupus.

After a dearth of dealmaking in recent years, acquisitions are on the upswing in the pharma industry. The second quarter was busy, with 14 biotech buyouts worth $50 million or more, according to data from BioPharma Dive. Just earlier this week, Amgen bought biotech company ChemoCentryx for nearly $4 billion.

Fri, 05 Aug 2022 09:13:00 -0500 en-US text/html https://www.biopharmadive.com/news/gilead-mirobio-deal-autoimmune/628941/
Killexams : Gilead Sciences to Acquire MiroBio

– Acquisition Provides Gilead with MiroBio's Pipeline of Immune Checkpoint Agonists and Proprietary Discovery Platform –

– MiroBio's Scientific Approach to Restoring Immune Balance for the Treatment of Autoimmune Diseases Complements Gilead's Inflammation Research and Development Strategy –

Gilead Sciences, Inc. GILD and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803006081/en/

The acquisition will provide Gilead with MiroBio's proprietary discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio's lead investigational antibody, MB272, is a selective agonist of immune inhibitory receptor B- and T-Lymphocyte Attenuator (BTLA) and has entered Phase 1 clinical trials, with the first patient dosed earlier this week. MB272 targets T, B and dendritic cells to inhibit or blunt activation and suppress an inflammatory immune response.

MiroBio's I-ReSToRE platform (REceptor Selection and Targeting to Reinstate immune Equilibrium) has the potential to be used to develop best-in-class agonist antibodies targeting immune inhibitory receptors, a novel approach to the treatment of inflammatory diseases. The I-ReSToRE platform supports identification and development of therapeutics that utilize inhibitory signaling networks with the goal of restoring immune homeostasis for patients. Gilead anticipates advancing additional agonists derived from MiroBio's I-ReSToRE platform, including a PD-1 agonist, MB151, and other undisclosed early-stage programs, over the next several years.

"The team at MiroBio has spearheaded foundational research for agonist antibodies following a rigorous scientific approach," said Flavius Martin, Executive Vice President, Research, Gilead Sciences. "We believe that MiroBio's unique platform technology has the potential to produce best-in-class agonist antibodies targeting immune inhibitory receptors."

"We are excited to be joining Gilead," said Eliot Charles, Chairman of MiroBio. "MiroBio has a deep understanding of checkpoint receptor signaling and a proprietary approach to select and generate superior agonist antibodies. Combining this with Gilead's drug development and therapeutic area expertise will allow us to fully explore the potential of checkpoint agonist antibodies for patients with autoimmune disease."

Under the terms of the agreement, Gilead will acquire all of the outstanding share capital of MiroBio for a total of $405 million in cash consideration, subject to customary adjustments, which is payable at closing. Beginning in the first quarter of 2022, consistent with recent industry communications from the U.S. Securities and Exchange Commission (SEC), Gilead no longer excludes acquired IPR&D expenses from its non-GAAP financial measures. We expect the transaction with MiroBio to reduce Gilead's GAAP and non-GAAP 2022 EPS by approximately $0.30-$0.35. Closing of the transaction is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

Cowen is acting as financial advisor to Gilead. Centerview Partners is acting as financial advisor to MiroBio. Davis Polk & Wardwell LLP, Mayer Brown LLP, and Mishcon de Reya LLP are serving as legal counsel to Gilead, and Goodwin Procter LLP and Wilson Sonsini Goodrich & Rosati are serving as legal counsel to MiroBio.

About MiroBio

MiroBio is a clinical-stage private biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune balance in autoimmune patients. MiroBio has developed I-ReSToRE, a proprietary discovery platform, combining its Checkpoint Atlas™, a cutting-edge receptor mapping database and visualization tool, with proprietary antibody engineering. It was spun out of Oxford University in 2019 and is based on more than 15 years of foundational research from the labs of Professor Simon Davis and Professor Richard Cornall with the potential to create safer and more efficacious medicines for patients with autoimmune disease. MiroBio is backed by a strong group of international investors including Oxford Science Enterprises, Samsara BioCapital, SR One, Medicxi, Advent Life Sciences, OrbiMed and Monograph.

For more information on MiroBio, please visit the company website: https://www.mirobio.com/

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of the parties to complete the transaction in a timely manner or at all; the possibility that various closing conditions for the transaction may not be satisfied or waived, including the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; uncertainties relating to the timing or outcome of any filings and approvals relating to the transaction; difficulties or unanticipated expenses in connection with integrating the companies, including the effects of the transaction on relationships with employees, other business partners or governmental entities; the risk that Gilead may not realize the expected benefits of this transaction; the ability of Gilead to advance MiroBio's product pipeline and successfully commercialize MiroBio's products; the ability of the parties to initiate and complete clinical trials involving such products in the currently anticipated timelines or at all; the possibility of unfavorable results from one or more of such trials involving such products; uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that FDA may not approve any such products in the anticipated indications or on the timelines or at all, and any marketing approvals, if granted, may have significant limitations on its use; any assumptions underlying any of the foregoing; and other risks and uncertainties detailed from time to time in Gilead's periodic reports filed with the U.S. Securities and Exchange Commission (the "SEC"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to Strengthen the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.

Thu, 04 Aug 2022 01:08:00 -0500 text/html https://www.benzinga.com/pressreleases/22/08/b28351838/gilead-sciences-to-acquire-mirobio
Killexams : MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--Jul 18, 2022--

MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that the first patient has been dosed in MAIA’s Phase 2 clinical trial, THIO-101, evaluating the administration of THIO, in sequence with cemiplimab, in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

The THIO-101 Phase 2 trial is designed to evaluate THIO’s potential immune system activation effects in NSCLC patients by administering THIO in advance of administration of the checkpoint inhibitor cemiplimab (developed by Regeneron), allowing for immune activation and PD-1 sensitivity to take effect. The primary objectives of the trial are to evaluate the safety and tolerability of THIO administered as a direct anticancer and priming immune system agent prior to cemiplimab administration, as well as the clinical efficacy of THIO in patients with advanced NSCLC who either progressed or relapsed through treatment with an immune-check point inhibitor alone or in combination with chemotherapy. The first patient in THIO-101 was dosed in Australia in July 2022 after the Company’s application received regulatory approval in March 2022. The Company also plans to submit a similar application in the second quarter of 2022, to conduct the same Phase 2 study in Europe.

“Dosing our first patient in this Phase 2 trial with THIO is an important milestone for MAIA, marking the continued development of our telomere-targeting approach,” said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. “Despite the advancements made in the field with checkpoint inhibitors, monoclonal antibodies and newer immunotherapies, very limited treatment options exist for patients that have progressed beyond the standard-of-care regimens. We believe THIO has the potential to hold a significant place in the NSCLC treatment paradigm.”

Sergei Gryaznov, Ph.D., Chief Scientific Officer of MAIA, added, “Lung cancer is the second most diagnosed cancer worldwide and NSCLC is the most common form of lung cancer, accounting for more than eighty percent of all lung cancer diagnoses. This represents a significant unmet medical need across the globe, and we remain enthusiastic about THIO’s observed mechanism of action.”

About THIO-101, a Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dosing finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO’s potential immune system activation effects in NSCLC patients by administering THIO in advance of administration of the checkpoint inhibitor cemiplimab (developed by Regeneron), potentially allowing for immune activation and PD-1 sensitivity to take effect. The trial will test the hypothesis that low doses of THIO administered prior to checkpoint inhibitor treatment will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or progressed after first-line treatment regimen containing a checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety of THIO administered as an anticancer agent and a priming immune system agent prior to cemiplimab administration and (2) to assess the clinical efficacy of THIO followed by cemiplimab using Overall Response Rate (ORR) as the primary clinical endpoint. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is an investigational telomere-targeting agent currently in clinical development to evaluate its activity in NSCLC. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed for patients with NSCLC that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully Strengthen and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in development for the treatment of patients with telomerase-positive cancers. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to Strengthen the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com:https://www.businesswire.com/news/home/20220718005297/en/

CONTACT: Investor Inquiries

ICR Westwicke

Stephanie Carrington

Stephanie.carrington@westwicke.com

646-277-1282

KEYWORD: ILLINOIS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY

SOURCE: MAIA Biotechnology, Inc.

Copyright Business Wire 2022.

PUB: 07/18/2022 08:00 AM/DISC: 07/18/2022 08:02 AM

http://www.businesswire.com/news/home/20220718005297/en

Mon, 18 Jul 2022 00:55:00 -0500 en text/html https://www.eagletribune.com/region/maia-biotechnology-doses-first-patient-with-thio-in-phase-2-trial-thio-101-for-non/article_fafe9c25-329e-562c-98a8-486eaffb4476.html
Killexams : Check Point (CHKP) Q2 Earnings & Revenues Top Estimates, Up Y/Y

Check Point Software Technologies CHKP reported strong second-quarter 2022 results, wherein both the top and bottom lines surpassed the respective Zacks Consensus Estimate and improved year over year.

The IT security solutions provider reported non-GAAP earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.62. The bottom line increased 2% from the year-ago quarter’s earnings of $1.61 per share.

Check Point’s quarterly revenues climbed 9% year over year to $571 million, outpacing the Zacks Consensus Estimate of $560.1 million. This upside was driven by double-digit growth in product and subscription revenues.

Check Point Software Technologies Ltd. Price, Consensus and EPS Surprise

Check Point Software Technologies Ltd. Price, Consensus and EPS Surprise

Check Point Software Technologies Ltd. price-consensus-eps-surprise-chart | Check Point Software Technologies Ltd. Quote

Quarterly Details

Subscription revenues were $209.9 million, advancing 14% year over year on double-digit revenues in Quantum and CloudGuard solutions and a 50% growth in Harmony, the cybersecurity firm’s cloud email security platform.

Products and licenses revenues increased 12% year over year to $133.2 million. Products, which are currently in the process of transitioning to cloud solutions, have been included in the subscription line.

Total revenues from product and security subscriptions were $343.1 million, up 13.3% year over year.

Software updates and maintenance revenues increased to $228 million from $223.3 million reported in the year-ago quarter.

As of Jun 30, 2022, deferred revenues were $1.67 billion, up 13% year over year.

Non-GAAP operating income for the second quarter of 2022 totaled $249 million, down from $257 million in the year-ago quarter. Non-GAAP operating margin contracted 500 basis points to 44%.

Balance Sheet & Other Details

Check Point exited the second quarter with cash and cash equivalents, marketable securities and short-term deposits of $3.68 billion compared with the previous quarter’s $3.80 billion.

The company generated cash worth $212 million from operational activities during the second quarter.

It repurchased 2.6 million shares for about $325 million during the reported quarter.

Outlook

For third-quarter 2022, CHKP expects revenues between $555 million and $585 million. It projects non-GAAP earnings to be in the $1.60-$1.72 per share band.

Zacks Rank & Key Picks

Check Point currently carries a Zacks Rank #3 (Hold). Shares of CHKP have decreased 6.4% in the past year.

Some better-ranked stocks from the broader Computer and Technology sector are Axcelis Technologies ACLS, Keysight Technologies KEYS and CrowdStrike CRWD. While Axcelis flaunts a Zacks Rank #1 (Strong Buy), Keysight and CrowdStrike each carry a Zacks Rank of 2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for Axcelis' second-quarter 2022 earnings has been revised 3 cents northward to $1.03 per share over the past seven days. For 2022, earnings estimates have moved 2 cents north to $4.40 per share in the past seven days.

Axcelis' earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 23.5%. Shares of ACLS have soared 79.6% in the past year.

The Zacks Consensus Estimate for Keysight's third-quarter fiscal 2022 earnings has been revised upward by a penny to $1.79 per share over the past 30 days. For 2023, earnings estimates have moved 3 cents north to $7.17 per share in the past 30 days.

Keysight’s earnings beat the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 8%. Shares of KEYS have fallen 1.9% in the past year.

The Zacks Consensus Estimate for CrowdStrike’s second-quarter fiscal 2023 earnings has been revised 11.5% northward to 29 cents per share over the past 60 days. For 2023, earnings estimates have moved 9.8% up to $1.23 per share in the past 60 days.

CrowdStrike’s earnings beat the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 44.3%. Shares of CRWD have decreased 28% in the past year.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Check Point Software Technologies Ltd. (CHKP) : Free Stock Analysis Report
 
Axcelis Technologies, Inc. (ACLS) : Free Stock Analysis Report
 
Keysight Technologies Inc. (KEYS) : Free Stock Analysis Report
 
CrowdStrike (CRWD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Tue, 02 Aug 2022 05:05:00 -0500 en-CA text/html https://ca.finance.yahoo.com/news/check-point-chkp-q2-earnings-150303954.html
Killexams : MAIA Biotechnology Doses First Patient With THIO in Phase 2 Trial (THIO-101) for Non-Small Cell Lung Cancer

CHICAGO, July 18, 2022--(BUSINESS WIRE)--MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs ("MAIA"), announced today that the first patient has been dosed in MAIA’s Phase 2 clinical trial, THIO-101, evaluating the administration of THIO, in sequence with cemiplimab, in patients with advanced Non-Small Cell Lung Cancer (NSCLC).

The THIO-101 Phase 2 trial is designed to evaluate THIO’s potential immune system activation effects in NSCLC patients by administering THIO in advance of administration of the checkpoint inhibitor cemiplimab (developed by Regeneron), allowing for immune activation and PD-1 sensitivity to take effect. The primary objectives of the trial are to evaluate the safety and tolerability of THIO administered as a direct anticancer and priming immune system agent prior to cemiplimab administration, as well as the clinical efficacy of THIO in patients with advanced NSCLC who either progressed or relapsed through treatment with an immune-check point inhibitor alone or in combination with chemotherapy. The first patient in THIO-101 was dosed in Australia in July 2022 after the Company’s application received regulatory approval in March 2022. The Company also plans to submit a similar application in the second quarter of 2022, to conduct the same Phase 2 study in Europe.

"Dosing our first patient in this Phase 2 trial with THIO is an important milestone for MAIA, marking the continued development of our telomere-targeting approach," said Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer. "Despite the advancements made in the field with checkpoint inhibitors, monoclonal antibodies and newer immunotherapies, very limited treatment options exist for patients that have progressed beyond the standard-of-care regimens. We believe THIO has the potential to hold a significant place in the NSCLC treatment paradigm."

Sergei Gryaznov, Ph.D., Chief Scientific Officer of MAIA, added, "Lung cancer is the second most diagnosed cancer worldwide and NSCLC is the most common form of lung cancer, accounting for more than eighty percent of all lung cancer diagnoses. This represents a significant unmet medical need across the globe, and we remain enthusiastic about THIO’s observed mechanism of action."

About THIO-101, a Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dosing finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO’s potential immune system activation effects in NSCLC patients by administering THIO in advance of administration of the checkpoint inhibitor cemiplimab (developed by Regeneron), potentially allowing for immune activation and PD-1 sensitivity to take effect. The trial will test the hypothesis that low doses of THIO administered prior to checkpoint inhibitor treatment will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or progressed after first-line treatment regimen containing a checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety of THIO administered as an anticancer agent and a priming immune system agent prior to cemiplimab administration and (2) to assess the clinical efficacy of THIO followed by cemiplimab using Overall Response Rate (ORR) as the primary clinical endpoint. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About THIO

THIO (6-thio-dG or 6-thio-2’-deoxyguanosine) is an investigational telomere-targeting agent currently in clinical development to evaluate its activity in NSCLC. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed for patients with NSCLC that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully Strengthen and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in development for the treatment of patients with telomerase-positive cancers. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to Strengthen the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, "MAIA," "Company," "we," "our," and "us" refers to MAIA Biotechnology, Inc. and its subsidiaries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220718005297/en/

Contacts

Investor Inquiries
ICR Westwicke
Stephanie Carrington
Stephanie.carrington@westwicke.com
646-277-1282

Mon, 01 Aug 2022 07:47:00 -0500 en-CA text/html https://ca.news.yahoo.com/maia-biotechnology-doses-first-patient-120000729.html
156-730 exam dump and training guide direct download
Training Exams List